Stay updated with breaking news from Breakthrough Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Soleno Therapeutics, Inc. announced that data from the randomized withdrawal period of Study C602 of DCCR extended-release tablets in Prader-Willi Syndrome will be featured in an oral presentation...
REDWOOD CITY, Calif., April 30, 2024 -- Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the...
First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned...
/PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its...
The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible. A prospective, blinded study by a research team